If you made any changes in Pure these will be visible here soon.

Personal profile

Research interests

Dr. Richard Mailman has had a decades-long interest in the design and discovery of novel dopamine receptor ligands.

The Mailman lab was also the first to discover, elaborate, and name (in 1994) the major pharmacology research front now called functional selectivity (how drugs acting at a single receptor differentially activate or block selected signaling pathways of that receptor).

Dr. Mailman's current research uses both dopamine D1 and D2 receptors as a model system and target for drug discovery. He is especially interested in the discovery of ligands with agonist properties at the D1 receptor, with data showing that D1 agonists can provide useful therapy in mid- and late-stage Parkinson’s disease, for improving deficits in cognition and memory, for ADHD, and even possibly for and Huntington’s disease. 

Dr. Mailman's current research in this area is focused on typical agonists with improved drugability, on functionally selective D1-like ligands, and the discovery of D1 or D5 selective ligands. The lab has recently identified a lead compound that is a potential clinical candidate and for which it has already demonstrated anti-Parkinson efficacy in non-human primates.

The lab's second focus is on functional selectivity of the D2 receptor. Here, they are interested in how small changes to drug-induced/selected conformations of the D2 receptor cause major differences in the signaling profiles of the receptor, and how resulting models may help design and discover functionally selective D2 ligands. 

The Mailman lab has played a major role in the understanding of aripiprazole (Abilify) pharmacology and in the path that brought it to the clinic. Moreover, the only D1 agonists currently available for clinical experimentation were discovered and developed by the Mailman group.

Dr. Mailman has active collaborations with the Parkinson’s disease research group at Penn State College of Medicine headed by Dr. Xuemei Huang.

Fingerprint Dive into the research topics where Richard Mailman is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 1 Similar Profiles

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Projects

  • CHILD DEVELOPMENT AND MENTAL RETARDATION

    Mailman, R., Suzuki, K., Suzuki, K., Helms, R. W., Suzuki, K. & Suzuki, K.

    National Institutes of Health

    9/1/777/31/98

    Project: Research project

  • Research Output

    Brain cholesterol metabolism and Parkinson's disease

    Huang, X., Sterling, N. W., Du, G., Sun, D., Stetter, C., Kong, L., Zhu, Y., Neighbors, J., Lewis, M. M., Chen, H., Hohl, R. J. & Mailman, R. B., Mar 2019, In : Movement Disorders. 34, 3, p. 386-395 10 p.

    Research output: Contribution to journalArticle

  • 6 Scopus citations

    Cancer and the dopamine D2 receptor: A pharmacological perspective

    Weissenrieder, J. S., Neighbors, J. D., Mailman, R. B. & Hohl, R. J., Jan 1 2019, In : Journal of Pharmacology and Experimental Therapeutics. 370, 1, p. 111-126 16 p.

    Research output: Contribution to journalReview article

  • 3 Scopus citations

    Higher Hippocampal Mean Diffusivity Values in Asymptomatic Welders

    Lee, E. Y., Flynn, M. R., Du, G., Lewis, M. M., Kong, L., Yanosky, J. D., Mailman, R. B. & Huang, X., Apr 1 2019, In : Toxicological Sciences. 168, 2, p. 486-496 11 p.

    Research output: Contribution to journalArticle

  • 1 Scopus citations

    Characterization of the neurochemical and behavioral effects of solriamfetol (JZP-110), a selective dopamine and norepinephrine reuptake inhibitor

    Baladi, M. G., Forster, M. J., Gatch, M. B., Mailman, R., Hyman, D. L., Carter, L. P. & Janowsky, A., Aug 1 2018, In : Journal of Pharmacology and Experimental Therapeutics. 366, 2, p. 367-376 10 p.

    Research output: Contribution to journalArticle

  • 18 Scopus citations
  • 2 Scopus citations